Indications for use of Ketotifen Sopharma are:

• atopic bronchial asthma;
• pollinosis (hay fever);
• allergic rhinitis;
• allergic conjunctivitis;
• atopic dermatitis;
• hives.

  Pharmachologic effect:

Stabilizer of mast cell membranes, has a moderate H1-histamine blocking activity, inhibits the release of histamine, leukotrienes from basophils and neutrophils, reduces the accumulation of eosinophils in the respiratory tract and the reaction to histamine, suppresses early and late asthmatic reactions to the allergen. Prevents the development of bronchospasm, does not have a bronchodilating effect. Inhibits phosphodiesterase, resulting in increased cAMP content in adipose tissue cells.

The therapeutic effect is fully manifested in 1.5-2 months from the start of therapy.

  Pharmacokinetics:

Absorption - almost complete, bioavailability - about 50% (due to the "first pass" effect through the liver). The time to reach Cmax is 2-4 hours, the connection with plasma proteins is 75%.

Passes through the blood-brain barrier. Penetrates into breast milk.

Metabolized in the liver. It is excreted by the kidneys in the form of metabolites (the main metabolite - ketotifen N-glucuronide is pharmacologically inactive). Within 48 hours, the kidneys excrete the main part of the dose taken (1% - unchanged and 60-70% - in the form of metabolites). Withdrawal - two-phase: T1 / 2 of the first phase - 3-5 hours, the second -21 hours.

Pharmacokinetics in children over 3 years old does not differ from adults.